ClinicalTrials.gg
CompletedNCT01980654Updated Apr 16, 2019Results posted

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

A Phase 2 interventional study of Ibrutinib and rituximab in Follicular Lymphoma, B-cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing ibrutinib in Lymphoma, Follicular — none open to participants now, 7 under way, 1 of them phase 3. ibrutinib · Lymphoma, Follicular.

Enrollment
7th of 24
80 · median 48
Started
2013
with 5 others
Phase 2
10 of 24
none open now
Registered
9th of 24
by date
Lead sponsor
4 of 24
Pharmacyclics LLC.

Among the 24 studies testing ibrutinib in Lymphoma, Follicular, this one is the 7th largest by enrollment, is one of 6 that started in 2013, is one of 10 in phase 2, and was the 9th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 24 studies testing ibrutinib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing ibrutinib in Lymphoma, Follicular as a file.
02

Study summary

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).

Read the detailed description

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with FL.

There are two study treatment arms.

Subjects enrolled into main study treatment arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.

Subjects enrolled into the exploratory study treatment arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.

03

Conditions studied

  • Follicular Lymphoma
  • B-cell Lymphoma
  • Non-Hodgkin's Lymphoma

Keywords

  • Pharmacyclics (PCYC)
  • PCYC
  • Lymphoma
  • Follicular Lymphoma
  • FL
  • Rituximab
  • Ibrutinib
  • Rituxan
  • Non-Hodgkin's Lymphoma (NHL)
  • NHL
  • B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. documented FL (Grade 1, 2 and 3A)
  2. Not previously treated with prior anti-cancer therapy for FL
  3. Stage II, III or IV disease
  4. At least one ≥ 2 cm in longest diameter by CT and/or MRI scan
  5. Men and women ≥ 18 years of age
  6. (ECOG) performance status of ≤ 2

Key Exclusion criteria:

  1. Medically apparent central nervous system lymphoma or
  2. FL with evidence of large cell transformation
  3. Any prior history of other hematologic besides FL or myelodysplasia
  4. History of other malignancies, except

    1. Malignancy treated with curative intent and with no known active disease present for ≥5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated non-melanoma skin cancer or lentigomaligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
  5. Currently active, cardiovascular disease or myocardial infarction within 6 months of screening
  6. Known anaphylaxis or Immunoglobulin E (IgE)-mediated to murine proteins or to any component of rituximab (Rituxan®)
  7. Requires anti-coagulation with warfarin or a vitamin K antagonist.
  8. Requires treatment with strong cytochrome P450 (CYP) 3A inhibitors.
  9. Known bleeding diathesis or hemophilia
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Main Study Arm 1

    Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.

    Drug: Ibrutinib · Drug: rituximab

  • Experimental
    Exploratory Study Arm 2

    Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.

    Drug: Ibrutinib · Drug: rituximab

Interventions

  • All subjects will receive 560 mg of Ibrutinib orally.

    Also known as: PCI-32765

  • All subjects will receive rituximab 375 mg/m2 intravenously

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR)

    Number of subjects achieving the best overall responses of CR or PR prior to the initiation of the next line of antineoplastic therapy as assessed by investigator per the Cheson et al, 2007 criteria. Target lesions are measured by CT, unless MRI is used as the assessment modality for lesions in anatomical locations not amenable to CT. CR is defined as the disappearance of all evidence of disease. PR is defined as \>=50% decrease in the sum of the product of the diameters of up to 6 largest dominant masses.

    Time frame: Subjects in Arm 1 will have imaging assessments every 12 weeks for the first 8 assessments, then every 24 weeks. Subjects in Arm 2 will have imaging assessments starting at week 9, then every 12 weeks for 8 assessments, then every 24 weeks.

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the interval between the date of the first documented response (CR, PR) and the date of the first documented evidence of progressive disease (PD) or death. DOR will be analyzed for the subjects who achieve an overall response during the duration of study.

    Time frame: Up to 45 months

  2. Progression Free Survival (PFS)

    PFS is defined as the time interval between the date of the first dose and the date of the earliest occurrence of PD or death due to any cause, whichever occurs first. PD is characterized by any new lesion or increase by \>=50% of previously involved sites from nadir.

    Time frame: Up to 45 months

  3. Overall Survival (OS)

    Subjects will be followed for survival information up to three years after the last dose of study treatment, until new treatment or death, whichever occurs first. OS is defined as the duration of time from the date of the first dose to the date of death from any cause.

    Time frame: Up to 45 months

  4. Number of Participants With Treatment-emergent Adverse Events

    Frequency, severity, and relatedness of treatment-emergent adverse events (AEs) Frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions

    Time frame: Up to 45 months

07

Results

Posted Apr 16, 2019

Participant flow

Participant flow — Overall Study
MilestoneMain Study Arm 1Exploratory Study Arm 2
Started6020
Completed6020
Not completed00

Outcome measures

PrimaryOverall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR)

Number of subjects achieving the best overall responses of CR or PR prior to the initiation of the next line of antineoplastic therapy as assessed by investigator per the Cheson et al, 2007 criteria. Target lesions are measured by CT, unless MRI is used as the assessment modality for lesions in anatomical locations not amenable to CT. CR is defined as the disappearance of all evidence of disease. PR is defined as \>=50% decrease in the sum of the product of the diameters of up to 6 largest dominant masses.

Time frame:
Subjects in Arm 1 will have imaging assessments every 12 weeks for the first 8 assessments, then every 24 weeks. Subjects in Arm 2 will have imaging assessments starting at week 9, then every 12 weeks for 8 assessments, then every 24 weeks.
Reported as:
Count of participants · Participants
Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR)
ParticipantsMain Study Arm 1Exploratory Study Arm 2
Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR)5115
SecondaryDuration of Response (DOR)

DOR is defined as the interval between the date of the first documented response (CR, PR) and the date of the first documented evidence of progressive disease (PD) or death. DOR will be analyzed for the subjects who achieve an overall response during the duration of study.

Time frame:
Up to 45 months
Reported as:
Median · months
Duration of Response (DOR)
monthsMain Study Arm 1Exploratory Study Arm 2
Duration of Response (DOR)NA (30.1602 to NA)NA (24.6078 to NA)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time interval between the date of the first dose and the date of the earliest occurrence of PD or death due to any cause, whichever occurs first. PD is characterized by any new lesion or increase by \>=50% of previously involved sites from nadir.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsMain Study Arm 1Exploratory Study Arm 2
Progression Free Survival (PFS)41.922 (31.6057 to 41.9220)NA (23.4908 to NA)
SecondaryOverall Survival (OS)

Subjects will be followed for survival information up to three years after the last dose of study treatment, until new treatment or death, whichever occurs first. OS is defined as the duration of time from the date of the first dose to the date of death from any cause.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival (OS)
monthsMain Study Arm 1Exploratory Study Arm 2
Overall Survival (OS)41.922 (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events

Frequency, severity, and relatedness of treatment-emergent adverse events (AEs) Frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsMain Study Arm 1Exploratory Study Arm 2
Subjects with any treatment-emergent AE6020
Subjects with any treatment-emergent AE Grade >=33914
Subjects with any treatment-related AE5920
Subjects with any treatment-related AE Grade >=32914
Subjects with any Ibrutinib-related AE5720
Subjects with any Ibrutinib-related AE Grade >=32914
Subjects with any Rituximab-related AE5017
Subjects with any Rituximab-related AE Grade >=3117
TEAE leading to ibrutinib dose reduction95
TEAE Grade >=3 leading to Ibrutinib dose reduction64
TEAE leading to witholding Rituximab11
TEAE Grade >=3 leading to witholding Rituximab11
TEAE leading to discontinuation of Ibrutinib142
TEAE Grade >=3 leading to discontinuation of Ibrut111
TEAE leading to discontinuation of Rituximab00
TEAE Grade >=3 leading to discontinuation of Ritux00
Subjects with any TE Serious Adverse Event (SAE)146
Subjects with any TE SAE Grade >=3135
Ibrutinib-related SAEs64
Ibrutinib-related SAEs Grade >=364
Rituximab-related SAEs22
Rituximab-related SAEs Grade >=322

Adverse events

Collected over 3 years, 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study Arm 14/60 (6.7%)14/60 (23.3%)60/60 (100%)
Exploratory Study Arm 20/20 (0%)6/20 (30%)20/20 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventMain Study Arm 1Exploratory Study Arm 2
PyrexiaGeneral disorders2/603/20
DiarrhoeaGastrointestinal disorders0/602/20
PneumoniaInfections and infestations2/602/20
Rectal haemorrhageGastrointestinal disorders0/601/20
Non-cardiac chest painGeneral disorders0/601/20
Urinary tract infectionInfections and infestations1/601/20
Clostridium difficile colitisInfections and infestations0/601/20
InfluenzaInfections and infestations0/601/20
MyalgiaMusculoskeletal and connective tissue disorders0/601/20
TendonitisMusculoskeletal and connective tissue disorders0/601/20
Most frequent other events
Showing 10 of 193
Most frequent other events
EventMain Study Arm 1Exploratory Study Arm 2
FatigueGeneral disorders41/6015/20
DiarrhoeaGastrointestinal disorders34/6012/20
StomatitisGastrointestinal disorders10/6011/20
NauseaGastrointestinal disorders29/6010/20
MyalgiaMusculoskeletal and connective tissue disorders20/609/20
DizzinessNervous system disorders13/609/20
ParaesthesiaNervous system disorders9/608/20
Rash maculo-papularSkin and subcutaneous tissue disorders18/608/20
Upper respiratory tract infectionInfections and infestations13/607/20
ArthralgiaMusculoskeletal and connective tissue disorders20/603/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Main Study Arm 1Exploratory Study Arm 2Total
<=18 years000
Between 18 and 65 years421254
>=65 years18826
Age, Continuous
Age, Continuous(years)Main Study Arm 1Exploratory Study Arm 2Total
Median58.0 (32 to 84)55.0 (30 to 75)58.0 (30 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Main Study Arm 1Exploratory Study Arm 2Total
Female32840
Male281240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study Arm 1Exploratory Study Arm 2Total
Hispanic or Latino336
Not Hispanic or Latino571774
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study Arm 1Exploratory Study Arm 2Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American213
White561874
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Main Study Arm 1Exploratory Study Arm 2Total
United States602080
Baseline B-Symptoms
Baseline B-Symptoms(Participants)Main Study Arm 1Exploratory Study Arm 2Total
B-Symptoms present prior to first dose404
B-Symptoms absent562076
Baseline Eastern Cooperative Oncology Group (ECOG) Score
Baseline Eastern Cooperative Oncology Group (ECOG) Score(Participants)Main Study Arm 1Exploratory Study Arm 2Total
Baseline ECOG Score = 0471259
Baseline ECOG Score = 113821
08

Study locations

12 sites
  • Providence Saint Joseph Medical Center
    Burbank, California 91505, United States
  • City of Hope
    Duarte, California 91010, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford University, Stanford Care Center
    Stanford, California 94305, United States
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • Community Health Network Community Regional Cancer Center North
    Indianapolis, Indiana 46256, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College New York-Presbyterian Hospital
    New York, New York 10065, United States
  • Mid-Ohio Oncology/ Hematology Inc
    Columbus, Ohio 43219, United States
  • Tennessee Oncology, PLLC The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Nov 11, 2013
Start
Dec 2013
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Results first posted
Apr 16, 2019
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01980654
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Dec 2013
Primary completion
Nov 2017
Completion
Nov 2017
Results posted
Apr 16, 2019
Last update
Apr 16, 2019

Study contacts

Jutta K. Neuenburg, MD, PhD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Rituximab

Start the discussion